<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

CU Cancer Center News and Stories

Multiple Myeloma

Research    Ovarian Cancer    Multiple Myeloma

Guidelines for Preventing Blood Clots in People With Cancer 

Many of the side effects of cancer treatment are well-known, including nausea, fatigue, and weight loss. 

Author Greg Glasgow | Publish Date July 28, 2023
Full Story

Community    Blood Cancer    Leukemia    Multiple Myeloma

The Latest on CAR T-Cell Therapy

September is Blood Cancer Awareness Month, a time for bringing attention to leukemia, lymphoma, myeloma, Hodgkin’s disease, and other blood cancers.

Author Greg Glasgow | Publish Date September 16, 2022
Full Story

Research    Community    Support    Magazine    Multiple Myeloma

A Woman Who Lived in the Light Inspires Research of the Cancer She Wouldn’t Let Defeat Her

Michael Joseph Roark – Mike to his friends – met Mary Jo Dougherty in a ski fitness class taught by Anne Kashiwa at the former International Athletic Club in downtown Denver.

Author Rachel Sauer | Publish Date May 05, 2022
Full Story

Multiple Myeloma

From hours to live to thriving: Johnna's story

Johnna Vinson knew something was very wrong, but she couldn’t seem to get an answer even after months of testing. In July of 2017 she found herself in the emergency room with the words “another 24 hours and you probably wouldn’t be here” hanging over her head. Intensive treatment at the University of Colorado Cancer Center saved her life and helped her find her “new normal”.

A long journey to answers

Johnna, a retired Navy Corpsman walked the stairs nearly every day at her office building in downtown Denver. In March of 2017 she noticed that doing the stairs were getting harder instead of easier and she couldn’t catch her breath. Johnna also began noticing random bruises all over her body, some as small as a pinprick and some as large as a baseball. In May, a sharp pain across her chest landed her in the ER due to a history of pulmonary embolism. Labs showed that the protein count in Johnna’s blood was elevated and recommended she follow up with her PCP. She was diagnosed with anemia and started taking iron supplements, but it did not help the symptoms. Finally, in July of 2017, Johnna had a complete rework of labs.

“I remember the day my doctor called me because it was a Saturday morning and it is never good to hear from your doctor on a Saturday morning,” says Johnna. “She told me something was very wrong, but she wasn’t sure what.”

In the midst of trying to get an answer, Johnna went in for an endoscopy. After the procedure her husband reached out to a family friend who is a radiologist and shared the lab results with him.

“Hours later my husband told me that our friend said ‘Johnna needs a transfusion now,’” says Johnna. “I didn’t want to panic so I called the afterhours help line at the hospital and spoke with a fellow that looked at my lab report. He said to me ‘if you were my mother or my sister you would be in the ER for a blood transfusion’. We went right to the hospital.”

When Johnna arrived at the ER her health was declining rapidly. Her kidneys were failing, she needed a transfusion immediately, and for the first time she heard the emergency doctors mention multiple myeloma. She was admitted to the hospital and the next day the diagnosis was confirmed.

Multiple myeloma is a blood cancer that occurs when a plasma cell, which is a type of white blood cell, releases excess protein in to bones and blood. This excess protein can cause organ damage.

On the uphill

Johnna met with Peter Forsberg, MD, member of the blood cancer and BMT team at the CU Cancer Center. She was immediately started on a regimen of chemotherapy and spent eight days in the hospital. After being released she continued to come back to the CU Cancer Center for weekly infusions. Unfortunately, the chemo did not work, and the cancer cells increased. Dr. Forsberg decided to switch Johnna to an immunotherapy.

“Johnna’s case is unique because the majority of patients that receive the initial therapy respond,” explains Forsberg. “It’s fairly rare not to achieve any response at all.  We changed her to a different combination that included the drug Daratumumab.”

Daratumumab is an FDA approved drug that targets a protein that is often overexpressed in multiple myeloma cancer cells. For Johnna, the drug was a miracle worker.

“I trust Dr. Forsberg with my life,” says Johnna. “He is absolutely fantastic. When he said that he thought it would be a good idea to start Daratumumab, I never questioned it.”

After nearly a year on the immunotherapy dug, Johnna stabilized to a point where she could have a stem cell transplant.

“Before my transplant I decided to shave my head on a Facebook live post so that no one would be shocked when they saw me without hair,” says Johnna. “My niece made t-shirts my entire family wore that said ‘GI Johnna’ and it was really a special moment. I didn’t get choked up until the very end when I saw my bald head. That’s when it really hit me.”

After the transplant Johnna’s cancer is in remission.

“I am just so grateful. I am grateful for Dr. Forsberg, I am grateful for the staff at the hospital, I am grateful to be alive,” she says. “Myeloma is not curable, it is impossible to tell what the future holds, but for now I am truly enjoying every moment of my life and only doing things that I really want to do.”

Finding the new normal

After going through more than a year of treatment and finishing with a successful stem cell transplant, Johnna had to find a new “normal” after cancer.

Johnna on a cruise smiling at the camera.
Johnna on a cruise with a friend after finishing treatment

“You get so used to being on a schedule with infusions and appointments,” she says. “When it is all over it really takes some time to adjust because your life is not the same as it was before cancer.”

One aspect of the new normal for Johnna was incorporating a healthy lifestyle.

“I heard about the BfitBwell program at my clinic. Once the transplant was over, I knew I needed to be a part of it,” she says. “The program is amazing. It not only helps you physically but also emotionally and mentally. I would recommend that any patient with cancer go through the program.”

Johnna still goes to the Anschutz Health and Wellness Center a couple times a week to keep up with her routine and say hi to her former trainers.

“They couldn’t get rid of me if they tried,” she jokes.

After a brush with death, Johnna has decided that life to too short to do things you don’t want to do.

“I remember telling my husband the day I was diagnosed that I was done wasting time doing things that I didn’t want to,” she says. “It changes your entire perspective when you don’t know if you have days, weeks, or months to live.”

True to her word Johnna is doing exactly what she wants to do – traveling and enjoying her loved ones.

Author Cancer Center | Publish Date June 02, 2019
Full Story

CU Cancer Center In the News

Cure Today

Caring for Patients with Sarcoma is a Team Effort, Expert Says

news outletCure Today
Publish DateJuly 12, 2024

University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.

Full Story

The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors

news outletOncLive
Publish DateJuly 08, 2024

CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.

Full Story
News Medical

Study shows effectiveness of treating pancreatic cancer patients with chemotherapy before surgery

news outletNews Medical
Publish DateJune 19, 2024

A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.

Full Story
Cancer Network

Liso-cel May Show Benefit in Earlier Therapy Lines for Lymphoma Subgroups

news outletCancer Network
Publish DateJune 14, 2024

In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.

Full Story